MC4R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
RNA interference (RNAi) The sequence-specific suppression of gene expression, natural or artificial, by any of a variety of RNA species capable of repressing transcription or translation through a variety of mechanisms. In the traditional usage, RNAi refers to the process by which small interfering RNA (siRNA) or short hairpin RNA (shRNA) molecules, as part of an RNA-induced silencing complex (RISC), identify and cleave foreign double-stranded RNA molecules and then use the cleaved single-stranded fragments to hybridize with complementary sequences in target messenger RNA (mRNA) transcripts and thus promote their degradation or otherwise inhibit translation. The term is also sometimes used more broadly to include silencing by antisense RNA (asRNA).
=== Engineering === MHD is related to engineering problems such as plasma confinement, liquid-metal cooling in nuclear reactors, and electromagnetic casting. A magnetohydrodynamic drive, or MHD propulsor, is a method for propelling seagoing vessels using only electric and magnetic fields, with no moving parts. The working principle involves electrifying the propellant (gas or water), which can then be directed by a magnetic field, thereby pushing the vehicle in the opposite direction. Although some working prototypes exist, MHD drives remain impractical. The first prototype of this type of propulsion was built and tested in 1965 by Steward Way, a professor of mechanical engineering at the University of California, Santa Barbara. While on leave from his job at Westinghouse Electric, Way assigned his senior-year undergraduate students to develop a submarine using this new propulsion system. In the early 1990s, the Ship & Ocean Foundation (Minato-ku, Tokyo) built an experimental boat, the Yamato-1, which used a magnetohydrodynamic drive incorporating a superconductor cooled by liquid helium and could travel at 15 km/h. MHD power generation fueled by potassium-seeded coal-combustion gas showed potential for more efficient energy conversion (the absence of solid moving parts allows operation at higher temperatures) but ultimately failed due to cost-prohibitive technical difficulties. One major engineering problem was the abrasion-induced failure of the wall of the primary-coal combustion chamber.
On 24 April 2007, for the first time, FDA officials said that melamine had been detected in feed given to animals raised for human consumption within the United States. As of 7 May 2007, United States food safety officials stated: "There is very low risk to human health from consuming meat from hogs and chickens known to have been fed animal feed supplemented with pet food scraps that contained melamine and melamine-related compounds"
The US, UK, and Soviet Union rejected it; US ambassador to the UN Thomas Pickering stated that the French proposal was unacceptable, because it went beyond Council resolutions on the Iraqi invasion. France dropped this proposal when it found "no tangible sign of interest" from Baghdad.
The Gravity Gun is first given to Gordon Freeman by his ally in the anti-Combine resistance, Alyx Vance, after which he uses it as both a weapon and tool. Certain objects in the game world, such as saw blades, can be used as de facto "ammunition", and the Zombie Chopper achievement rewards the player for beating the Ravenholm segment - an abandoned town infested by headcrab zombies - using only the Gravity Gun. Late in the game, Freeman is captured by the Combine and forced to relinquish all his weapons. However, in a sudden plot twist, the Gravity Gun is accidentally supercharged by the energy field meant to destroy it, turning blue and becoming capable of grabbing and throwing living objects, including the Combine themselves. This allows Freeman to escape and defeat the malevolent Doctor Breen.
Sources: en.wikipedia.org
=== Secondary polycythemia === Secondary polycythemia is caused by either natural or artificial increases in the production of erythropoietin, hence an increased production of erythrocytes. Secondary polycythemia in which the production of erythropoietin increases appropriately is called physiologic polycythemia. Conditions which may result in physiologic polycythemia include:
=== Steps of the urea cycle === Carbamoyl phosphate is converted to citrulline. With catalysis by ornithine transcarbamylase, the carbamoyl phosphate group is donated to ornithine and releases a phosphate group. A condensation reaction occurs between the amino group of aspartate and the carbonyl group of citrulline to form argininosuccinate. This reaction is ATP dependent and is catalyzed by argininosuccinate synthetase. Argininosuccinate undergoes cleavage by argininosuccinase to form arginine and fumarate. Arginine is cleaved by arginase to form urea and ornithine. The ornithine is then transported back to the mitochondria to begin the urea cycle again.
==== 1–99 ==== Environmental Protection (Controls on Injurious Substances) Regulations 1993 (S.I. 1993/1) Rail Crossing Extinguishment and Diversion Orders Regulations 1993 (S.I. 1993/9) Town and Country Planning (Public Path Orders) Regulations 1993 (S.I. 1993/10) Public Path Orders Regulations 1993 (S.I. 1993/11) Wildlife and Countryside (Definitive Maps and Statements) Regulations 1993 (S.I. 1993/12) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) Partial Revocation Order 1993 (S.I. 1993/13) Animals (Post-Import Control) Order 1993 (S.I. 1993/14) Genetically Modified Organisms (Contained Use) Regulations 1993 (S.I. 1993/15) Friendly Societies Act 1992 (Commencement No. 3 and Transitional Provisions) Order 1993 (S.I. 1993/16) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) Order 1993 (S.I. 1993/17) Wireless Telegraphy Apparatus (Land Mobile-Satellite Service) (Low Bit Rate Data) (Exemption) Regulations 1993 (S.I. 1993/21) Local Government Finance (Miscellaneous Provisions) (England) Order 1993 (S.I. 1993/22) Lanarkshire (Hamilton) Enterprise Zones Designation Order 1993 (S.I. 1993/23) Lanarkshire (Motherwell) Enterprise Zones Designation Order 1993 (S.I. 1993/24) Lanarkshire (Monklands) Enterprise Zones Designation Order 1993 (S.I. 1993/25) Mayday Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/27) Warrington Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/28) West Midlands Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I.
=== Anthropogenic influences === Anthropogenic industry unintentionally injects micronutrients into various ecosystems across the globe. The addition of micronutrients into ecosystems can have both positive and negative impacts. In the face of climate change, the fertilization of oceans with iron has been proposed as a method of carbon sequestration; however, elevated levels of iron in high nutrient, low chlorophyll regions of the ocean can cause the production of harmful algal blooms which are toxic to both humans and marine life. Similarly, in lakes, isolated seas, and coastal bays or gulfs, addition of micronutrients can cause eutrophication leading to hypoxia, decreasing ecosystem health. Micronutrients are released into ecosystems from many anthropogenic activities. Fossil fuel combustion releases micronutrients such as Zn, Fe, Ni, and Cu into the atmosphere, surrounding soils, and nearby waterways. Agricultural fertilizer runoff contains many micronutrients like Fe, Mn, Zn, Cu, Co, B, Mo and Ni. Fertilizer runoff injects these micronutrients into groundwater, soils, and waterways. Deforestation decreases soil compaction, resulting in increased aeolian transport of dust containing micronutrients, especially Fe. Industrial mining produces tailings which contaminates runoff. The improper treatment of mining tailings can result in the leakage of micronutrients into groundwater, soils, and nearby waterways.
The male pilot, who was the only person on board, is taken to hospital by air ambulance. In the first statement to be released since his cancer diagnosis, Charles III thanks the public for their messages of support. 11 February – British journalist Clare Rewcastle Brown accuses Malaysia of seeking "political revenge" for her reporting after a court jailed her in absentia for criminal defamation of a Malaysian royal. 12 February Azhar Ali, the Labour Party's Rochdale by-election candidate, is suspended from the party over comments about Israel and Jewish people. He will however remain on the ballot as the Labour candidate, as it is too late to replace him under electoral law. Three apologises after three days of outages that left around 12,000 people without mobile signals and data. Child killer Colin Pitchfork will be reconsidered for parole after successfully challenging a Parole Board decision to refuse him parole on the grounds he poses too much of a risk if released from prison. 13 February A catastrophic loss of seabird numbers is reported by the RSPB and the British Trust for Ornithology, due to the spread of H5N1 bird flu. Police begin an investigation into reports of antisemitism during a performance by comedian Paul Currie at the Soho Theatre in London, which left Jewish audience members feeling "unsafe" and "threatened". Labour leader Keir Starmer insists he took "decisive action" over comments made by Rochdale by-election candidate Azhar Ali. Cosmetics retailer The Body Shop enters administration, putting more than 2,200 jobs at risk.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.